The estimated Net Worth of Bernard J Kelley is at least $1.69 Milión dollars as of 10 August 2021. Mr. Kelley owns over 20,000 units of Codexis stock worth over $617,351 and over the last 13 years he sold CDXS stock worth over $864,657. In addition, he makes $204,989 as Independent Chairman of the Board at Codexis.
Sign up
Mr. Kelley CDXS stock SEC Form 4 insiders trading
Bernard has made over 16 trades of the Codexis stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of CDXS stock worth $72,400 on 10 August 2021.
The largest trade he's ever made was exercising 21,666 units of Codexis stock on 24 August 2016 worth over $53,082. On average, Bernard trades about 6,203 units every 80 days since 2011. As of 10 August 2021 he still owns at least 226,136 units of Codexis stock.
You can see the complete history of Mr. Kelley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Bernard Kelley biography
Bernard J. Kelley serves as an Independent Chairman of the Board of the Board of the Company. Mr. Kelley brings to our board of directors experience in pharmaceutical manufacturing, as well as senior management and financial operations experience. From 1993 to 2002, Mr. Kelley was the President of the Merck Manufacturing Division, a division of Merck & Co., Inc. (“Merck”), a global pharmaceutical company, and he served as a member of the Merck Management Committee from 1995 to 2002. Mr. Kelley previously served on the board of directors of Aegis Analytical Corporation, an enterprise software company, from 2004 to 2006, and on the board of directors and compensation and audit committees of MAP Pharmaceuticals, Inc., a biotechnology company focused on developing inhalation-based therapies which was acquired by Allergan, Inc. in March 2013, from May 2007 to March 2013. In addition, Mr. Kelley serves as a member of the board of trustees and the finance committee of the Catholic Foundation of Greater Philadelphia, a non-profit organization based in Philadelphia, and as a member of the board of trustees and finance committee of the National Liberty Museum, also a non-profit organization based in Philadelphia. Mr. Kelley holds a B.S. in engineering from the U.S. Naval Academy.
What is the salary of Bernard Kelley?
As the Independent Chairman of the Board of Codexis, the total compensation of Bernard Kelley at Codexis is $204,989. There are 4 executives at Codexis getting paid more, with John Nicols having the highest compensation of $3,408,030.
How old is Bernard Kelley?
Bernard Kelley is 78, he's been the Independent Chairman of the Board of Codexis since 2016. There are 1 older and 11 younger executives at Codexis. The oldest executive at Codexis Inc. is Thomas Baruch, 81, who is the Independent Director.
What's Bernard Kelley's mailing address?
Bernard's mailing address filed with the SEC is C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY, CA, 94063.
Insiders trading at Codexis
Over the last 15 years, insiders at Codexis have traded over $34,923,852 worth of Codexis stock and bought 399,963 units worth $1,488,111 . The most active insiders traders include Ventures Vii, Llc Vivo Vent..., Ventures Life Sciences 2000... a John J Nicols. On average, Codexis executives and independent directors trade stock every 32 days with the average trade being worth of $153,997. The most recent stock trade was executed by Byron L Dorgan on 15 November 2023, trading 20,000 units of CDXS stock currently worth $42,200.
What does Codexis do?
codexis, inc. is a leading protein engineering company applying innovative technologies to unlock the power of proteins™. our proprietary codeevolver® technology platform enables the rapid development and production of highly optimized proteins, custom-designed for your application. codexis’ revolutionary approach to protein engineering starts with an understanding of the desired performance specifications and optimizes a protein specifically to fit these requirements. you get precisely the protein you need for the job you want it to do. guided by proprietary artificial intelligence software and advanced high-throughput screening systems, codexis is able to efficiently generate and introduce function-driven mutations to rapidly improve a protein for its target application. since 2002, codexis’ in-house biochemists, biologists and bioinformatics experts have worked closely with our clients to advance the technologies for protein optimization and production, enabling breakthrough develop
What does Codexis's logo look like?
Complete history of Mr. Kelley stock trades at Codexis
Codexis executives and stock owners
Codexis executives and other stock owners filed with the SEC include:
-
John Nicols,
President, Chief Executive Officer, Director -
John J. Nicols,
Pres, CEO & Director -
Ross Taylor Jr., M.B.A.,
Sr. VP & CFO -
Ross Taylor,
Chief Financial Officer, Senior Vice President -
Bernard Kelley,
Independent Chairman of the Board -
Byron Dorgan,
Independent Director -
Pam Cheng,
Independent Director -
David Smith,
Independent Director -
Patrick Yang,
Independent Director -
Dennis Wolf,
Independent Director -
Thomas Baruch,
Independent Director -
Jennifer Aaker,
Independent Director -
Karen Frechou-Armijo,
Sr. VP & Head of HR -
Asli Aras Ph.D.,
VP of Corp. Devel. -
Dr. Davinder Singh Brar,
Special Advisor to the Board -
Prof. Gerhard N. Mayr,
Special Advisor to the Board -
Robert Sato M.B.A., Ph.D.,
Sr. VP of Pharmaceutical Devel., Quality & Regulatory -
Dr. Stefan Lutz Ph.D.,
Sr. VP of Research -
Rob Wilson Ph.D.,
Sr. VP & GM of Performance Enzymes -
Dr. Gjalt Huisman Ph.D.,
Sr. VP of Strategic Devel. & GM of Biotherapeutics -
Dr. Karl A. Schoene Ph.D.,
Sr. VP of Devel. & Operations -
Kathleen Sereda Glaub,
Director -
Gordon Sangster,
SVP & Chief Financial Officer -
James Lalonde,
SVP, R&D -
Ventures Vii, Llc Vivo Vent...,
-
Douglas T. Sheehy,
SVP, Gen Counsel and Sec. -
Sriram Ryali,
Chief Financial Officer -
Ventures Fund Vii, L.P.Vivo...,
-
David D O'toole,
SVP & Chief Financial Officer -
Alexander Karsner,
Director -
Matthew Tobin,
SVP, Research & Development -
David L. Anton,
SVP, Research and Development -
Ventures Life Sciences 2000...,
-
James R Sulat,
Director -
Mun Yew Wong,
Director -
Brazil Holding B.V. Shell,
10% owner -
Bruce A Pasternack,
Director -
Robert J Lawson,
SVP and CFO -
Brian Paul Dowd,
Interim CFO -
Inc Maxygen,
10% owner -
Peter M Strumph,
Interim President and CEO -
Joseph J. Sarret,
CBO, President Pharmaceuticals -
Peter Seufer Wasserthal,
SVP, Pharmaceuticals -
Enterprises Llc Royal Dutch...,
-
Alan Shaw,
President and CEO -
Enterprises Llc Equilon,
10% owner -
Participacoes Ltda.Royal Du...,
-
Sciences Investment Fund Pt...,
-
Esther Martinborough,
-
H Stewart Parker,
-
Rahul Singhvi,
-
Alison Moore,
-
Margaret Nell Fitzgerald,
See Remarks -
Stephen George Dilly,
See Remarks -
Kevin Norrett,
Chief Operating Officer